Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Advanced age not linked with risk from nipple-sparing mastectomy

Cox S et al. and Bartholomew AJ et al. Session SF310 ACS Clinical Congress 2018

Key clinical point: Neoadjuvant chemotherapy and advancing age were not associated with increased rates of complications in women undergoing nipple-sparing mastectomy in two recent studies.

Major finding: The overall rate of complications was not significantly different for neoadjuvant chemotherapy vs. primary surgery (12.7% vs. 10.7%) or for age over 60 years vs. younger age (15.5% vs. 13.0%).

Study details: Retrospective studies of a nipple-sparing mastectomy registry including more than 3,000 breasts (neoadjuvant chemotherapy vs. primary surgery study) and a single-institution study of nearly 400 patients (older vs. younger study).

Disclosures: The authors reported no conflicts of interest.

Read the article here.

Citation:

Cox S et al. and Bartholomew AJ et al. Session SF310 ACS Clinical Congress 2018.

This Week's Must Reads

Lenvatinib plus pembrolizumab shows promising activity in NSCLC, Brose M et al. SITC 2018, Abstract P392

Advanced age not linked with risk from nipple-sparing mastectomy, Cox S et al. and Bartholomew AJ et al. Session SF310 ACS Clinical Congress 2018

Must Reads in Breast Cancer

Advanced age not linked with risk from nipple-sparing mastectomy, Cox S et al. and Bartholomew AJ et al. Session SF310 ACS Clinical Congress 2018

Avoiding topical agents prior to RT may be unnecessary, Baumann BC et al. JAMA Oncol. 2018 Oct 18. doi: 10.1001/jamaoncol.2018.4292

Men with MBC have a similar prognosis compared with women, Sirieix et al. ESMO 2018, Abstract 294PD; Reinisch et al. ESMO 2018, Abstract 273PD

Inherited mutations account for 12% of Nigerian breast cancer, Olopade et al. J Clin Oncol. 2018 Aug 21. doi: 10.1200/JCO.2018.78.3977.